peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

neurohypophyseal hormone

Oxytocin

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Pharmacokinetics

An in vitro stability/PK-like measurement in human serum reports a half-life (T1/2) of 11.6 hr for CHEMBL395429.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL395429Molecule: CHEMBL395429 Target: Serum (CHEMBL613426) Assay: Half life in human serum by LC/MS and RP-HPLC method Assay format: cell-free format Standard result: T1/2 = 11.6 hr Document: CHEMBL1629457
Reported result
T1/2 = 11.6 hr
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Molecule: CHEMBL395429 Target: Serum (CHEMBL613426) Assay: Half life in human serum by LC/MS and RP-HPLC method Assay format: cell-free format Standard result: T1/2 = 11.6 hr Document: CHEMBL1629457”

    ChEMBL activities for CHEMBL395429 · Activity 5119972

    chembl-activities:chembl395429:6b4ffd0c8db7:6b4ffd0c8db7

What has been studied?

What the evidence says.

Study findings

In labour dystocia management, oxytocin is used as the standard pharmacologic agent to augment (strengthen/regularize) uterine contractions.

Sources[2]pubmedEffect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.Although oxytocin is the standard therapy for augmentation,
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Although oxytocin is the standard therapy for augmentation,”

    Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial. · BACKGROUND

    pubmed:42480078:7f44bc6f3e93:7f44bc6f3e93

Study findings

Clinically, oxytocin is frequently administered to increase uterine contraction strength during labour.

Sources[2]pubmedEffect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.Oxytocin is commonly used to strengthen contractions,
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Oxytocin is commonly used to strengthen contractions,”

    Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial. · Abstract

    pubmed:42480078:7f44bc6f3e93:7f44bc6f3e93

Study findings

A functional reporter-gene assay in CHO-K1 cells shows CHEMBL395429 is an oxytocin receptor agonist with EC50 = 2.3 nM measured after 5 hrs.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL395429Molecule: CHEMBL395429 Target: Oxytocin receptor (CHEMBL2049) Assay: Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay Assay format: cell-based format Standard result: EC50 = 2.3 nM pChEMBL value: 8.64 Document: CHEMBL3351738
Reported result
EC50 = 2.3 nM
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Molecule: CHEMBL395429 Target: Oxytocin receptor (CHEMBL2049) Assay: Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay Assay format: cell-based format Standard result: EC50 = 2.3 nM pChEMBL value: 8.64 Document: CHEMBL3351738”

    ChEMBL activities for CHEMBL395429 · Activity 15001074

    chembl-activities:chembl395429:6b4ffd0c8db7:6b4ffd0c8db7

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, mechanism, regulatory, safety
  • 53 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (34), assurance_score_below_0.72 (18), current_regulatory_source_required (14), extraction_ambiguity (48), high_risk_requires_regulatory_or_two_independent_sources (17), no_direct_support (48)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. ChEMBL activities for CHEMBL395429 ↗

    chembl-activities · published 2026-08-28 · retrieved 2026-08-28T12:35:21Z

  2. Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial. ↗

    pubmed · published 2026-12-01 · retrieved 2026-08-28T12:35:21Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-30T08:40:08Z

e1e364d95e6763d58ed53751da5ac9eec2f4ceb2f286b17fb7a8cff140760fdd